Antipsychotic Use and Physical Morbidity in Parkinson Disease

Daniel Weintraub, Claire Chiang, Hyungjin Myra Kim, Jayne Wilkinson, Connie Marras, Barbara Stanislawski, Eugenia Mamikonyan, Helen C. Kales

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective To determine if antipsychotic (AP) use in Parkinson disease (PD) patients is associated with increased physical morbidity. Methods Veterans Health Administration data (1999–2010) was used to examine physical morbidity risk associated with AP use in idiopathic PD patients with stable recent physical health. We compared 180-day morbidity rates in patients initiating an AP with matched non-AP users who survived for 180 days (matched on age, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new non-psychiatric medications; covarying for psychosis). Outcomes were 180-day emergency department (ED), and inpatient and outpatient visits. Results There were 6,679 matched PD pairs. Any AP use was associated with an increased risk of ED visit (HR: 1.64, 95% CI: 1.51, 1.77), inpatient care (HR: 1.58, 95% CI: 1.46, 1.71), and outpatient visits (IRR: 1.08, 95% CI: 1.05, 1.12). The risk was significantly higher for atypical AP use compared with nonuse for all three morbidity outcomes, and was similar for atypical and typical AP use. Conclusions Any AP use, and atypical AP use, are associated with significantly increased physical morbidity risk in PD patients, as evidenced by increased ED, inpatient, and outpatient visits. These findings, which require replication, extend the risk associated with use of APs in this population from mortality to a broader range of adverse outcomes, and further highlight the need to use APs cautiously in PD patients.

Original languageEnglish (US)
Pages (from-to)697-705
Number of pages9
JournalAmerican Journal of Geriatric Psychiatry
Volume25
Issue number7
DOIs
StatePublished - Jul 2017
Externally publishedYes

Fingerprint

Antipsychotic Agents
Parkinson Disease
Morbidity
Hospital Emergency Service
Inpatients
Outpatients
Veterans Health
United States Department of Veterans Affairs
Delirium
Psychotic Disorders
Dementia
Comorbidity
Hospitalization
Mortality
Health
Population

Keywords

  • Antipsychotic
  • morbidity
  • Parkinson disease
  • psychosis

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., ... Kales, H. C. (2017). Antipsychotic Use and Physical Morbidity in Parkinson Disease. American Journal of Geriatric Psychiatry, 25(7), 697-705. https://doi.org/10.1016/j.jagp.2017.01.076

Antipsychotic Use and Physical Morbidity in Parkinson Disease. / Weintraub, Daniel; Chiang, Claire; Kim, Hyungjin Myra; Wilkinson, Jayne; Marras, Connie; Stanislawski, Barbara; Mamikonyan, Eugenia; Kales, Helen C.

In: American Journal of Geriatric Psychiatry, Vol. 25, No. 7, 07.2017, p. 697-705.

Research output: Contribution to journalArticle

Weintraub, D, Chiang, C, Kim, HM, Wilkinson, J, Marras, C, Stanislawski, B, Mamikonyan, E & Kales, HC 2017, 'Antipsychotic Use and Physical Morbidity in Parkinson Disease', American Journal of Geriatric Psychiatry, vol. 25, no. 7, pp. 697-705. https://doi.org/10.1016/j.jagp.2017.01.076
Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B et al. Antipsychotic Use and Physical Morbidity in Parkinson Disease. American Journal of Geriatric Psychiatry. 2017 Jul;25(7):697-705. https://doi.org/10.1016/j.jagp.2017.01.076
Weintraub, Daniel ; Chiang, Claire ; Kim, Hyungjin Myra ; Wilkinson, Jayne ; Marras, Connie ; Stanislawski, Barbara ; Mamikonyan, Eugenia ; Kales, Helen C. / Antipsychotic Use and Physical Morbidity in Parkinson Disease. In: American Journal of Geriatric Psychiatry. 2017 ; Vol. 25, No. 7. pp. 697-705.
@article{36fefe07ed3e4cfb8945af676971dcde,
title = "Antipsychotic Use and Physical Morbidity in Parkinson Disease",
abstract = "Objective To determine if antipsychotic (AP) use in Parkinson disease (PD) patients is associated with increased physical morbidity. Methods Veterans Health Administration data (1999–2010) was used to examine physical morbidity risk associated with AP use in idiopathic PD patients with stable recent physical health. We compared 180-day morbidity rates in patients initiating an AP with matched non-AP users who survived for 180 days (matched on age, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new non-psychiatric medications; covarying for psychosis). Outcomes were 180-day emergency department (ED), and inpatient and outpatient visits. Results There were 6,679 matched PD pairs. Any AP use was associated with an increased risk of ED visit (HR: 1.64, 95{\%} CI: 1.51, 1.77), inpatient care (HR: 1.58, 95{\%} CI: 1.46, 1.71), and outpatient visits (IRR: 1.08, 95{\%} CI: 1.05, 1.12). The risk was significantly higher for atypical AP use compared with nonuse for all three morbidity outcomes, and was similar for atypical and typical AP use. Conclusions Any AP use, and atypical AP use, are associated with significantly increased physical morbidity risk in PD patients, as evidenced by increased ED, inpatient, and outpatient visits. These findings, which require replication, extend the risk associated with use of APs in this population from mortality to a broader range of adverse outcomes, and further highlight the need to use APs cautiously in PD patients.",
keywords = "Antipsychotic, morbidity, Parkinson disease, psychosis",
author = "Daniel Weintraub and Claire Chiang and Kim, {Hyungjin Myra} and Jayne Wilkinson and Connie Marras and Barbara Stanislawski and Eugenia Mamikonyan and Kales, {Helen C.}",
year = "2017",
month = "7",
doi = "10.1016/j.jagp.2017.01.076",
language = "English (US)",
volume = "25",
pages = "697--705",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Antipsychotic Use and Physical Morbidity in Parkinson Disease

AU - Weintraub, Daniel

AU - Chiang, Claire

AU - Kim, Hyungjin Myra

AU - Wilkinson, Jayne

AU - Marras, Connie

AU - Stanislawski, Barbara

AU - Mamikonyan, Eugenia

AU - Kales, Helen C.

PY - 2017/7

Y1 - 2017/7

N2 - Objective To determine if antipsychotic (AP) use in Parkinson disease (PD) patients is associated with increased physical morbidity. Methods Veterans Health Administration data (1999–2010) was used to examine physical morbidity risk associated with AP use in idiopathic PD patients with stable recent physical health. We compared 180-day morbidity rates in patients initiating an AP with matched non-AP users who survived for 180 days (matched on age, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new non-psychiatric medications; covarying for psychosis). Outcomes were 180-day emergency department (ED), and inpatient and outpatient visits. Results There were 6,679 matched PD pairs. Any AP use was associated with an increased risk of ED visit (HR: 1.64, 95% CI: 1.51, 1.77), inpatient care (HR: 1.58, 95% CI: 1.46, 1.71), and outpatient visits (IRR: 1.08, 95% CI: 1.05, 1.12). The risk was significantly higher for atypical AP use compared with nonuse for all three morbidity outcomes, and was similar for atypical and typical AP use. Conclusions Any AP use, and atypical AP use, are associated with significantly increased physical morbidity risk in PD patients, as evidenced by increased ED, inpatient, and outpatient visits. These findings, which require replication, extend the risk associated with use of APs in this population from mortality to a broader range of adverse outcomes, and further highlight the need to use APs cautiously in PD patients.

AB - Objective To determine if antipsychotic (AP) use in Parkinson disease (PD) patients is associated with increased physical morbidity. Methods Veterans Health Administration data (1999–2010) was used to examine physical morbidity risk associated with AP use in idiopathic PD patients with stable recent physical health. We compared 180-day morbidity rates in patients initiating an AP with matched non-AP users who survived for 180 days (matched on age, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new non-psychiatric medications; covarying for psychosis). Outcomes were 180-day emergency department (ED), and inpatient and outpatient visits. Results There were 6,679 matched PD pairs. Any AP use was associated with an increased risk of ED visit (HR: 1.64, 95% CI: 1.51, 1.77), inpatient care (HR: 1.58, 95% CI: 1.46, 1.71), and outpatient visits (IRR: 1.08, 95% CI: 1.05, 1.12). The risk was significantly higher for atypical AP use compared with nonuse for all three morbidity outcomes, and was similar for atypical and typical AP use. Conclusions Any AP use, and atypical AP use, are associated with significantly increased physical morbidity risk in PD patients, as evidenced by increased ED, inpatient, and outpatient visits. These findings, which require replication, extend the risk associated with use of APs in this population from mortality to a broader range of adverse outcomes, and further highlight the need to use APs cautiously in PD patients.

KW - Antipsychotic

KW - morbidity

KW - Parkinson disease

KW - psychosis

UR - http://www.scopus.com/inward/record.url?scp=85014068058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014068058&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2017.01.076

DO - 10.1016/j.jagp.2017.01.076

M3 - Article

C2 - 28259697

AN - SCOPUS:85014068058

VL - 25

SP - 697

EP - 705

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 7

ER -